Related Experiment Video
Updated: Jan 27, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
TRAIL-functionalized nanoparticles in cancer therapy: Molecular mechanisms and translational opportunities
Dasari Sahithi1, Urushi Rehman1, Ramasubbamma Ramaiah2
1Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent anticancer agent capable of selectively triggering apoptosis in malignant cells while sparing normal tissues. Clinical translation of TRAIL is limited by rapid systemic clearance, poor pharmacokinetics, and intrinsic or acquired tumor resistance. Nanotechnology offers innovative solutions by stabilizing TRAIL, enhancing bioavailability, and enabling targeted delivery. Lipid-based, polymeric, and metallic nanoparticles have been engineered to improve TRAIL activity and achieve tumor-specific accumulation. TRAIL-functionalized nanocarriers also facilitate combinatorial strategies, including co-delivery with chemotherapeutics, sensitizers, or immunomodulators, to overcome resistance and potentiate apoptotic signaling. Preclinical studies in triple-negative breast cancer, glioblastoma, and colorectal carcinoma models demonstrate enhanced therapeutic efficacy, reduced systemic toxicity, and significant translational potential. This review critically examines the molecular mechanisms of TRAIL-mediated apoptosis, design principles of TRAIL-conjugated nanoparticles, and their integration into synergistic therapeutic regimens. Current limitations and future directions are discussed, emphasizing strategies to advance TRAIL nanomedicines toward clinical application. Collectively, TRAIL-functionalized nanoparticles represent a promising approach to precision oncology, bridging molecular therapeutics and nanotechnology for personalized cancer treatment.
Insights
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) nanoparticles enhance cancer treatment by improving drug delivery and overcoming resistance. This nanotechnology approach shows promise for personalized cancer therapy.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces cancer cell death but faces clinical challenges like rapid clearance and tumor resistance.
- Nanotechnology provides solutions to stabilize TRAIL, improve its pharmacokinetics, and enable targeted delivery to tumors.
- TRAIL-based nanomedicines offer potential for overcoming drug resistance and enhancing apoptotic signaling in cancer treatment.
Purpose of the Study:
- To review the mechanisms of TRAIL-mediated apoptosis and the design of TRAIL-functionalized nanoparticles.
- To explore the integration of TRAIL nanomedicines with synergistic therapeutic strategies.
- To discuss the translational potential and future directions for TRAIL nanomedicines in precision oncology.
Main Methods:
- Review of preclinical studies on TRAIL-functionalized nanoparticles in various cancer models (e.g., triple-negative breast cancer, glioblastoma, colorectal carcinoma).
- Analysis of lipid-based, polymeric, and metallic nanoparticle designs for TRAIL delivery.
- Examination of combinatorial strategies involving TRAIL nanomedicines with chemotherapy, sensitizers, or immunomodulators.
Main Results:
- TRAIL-functionalized nanoparticles demonstrate enhanced therapeutic efficacy and tumor-specific accumulation.
- These nanocarriers improve TRAIL bioavailability and stability, overcoming pharmacokinetic limitations.
- Combinatorial approaches using TRAIL nanoparticles show potential for overcoming intrinsic or acquired tumor resistance.
- Preclinical studies report reduced systemic toxicity compared to conventional TRAIL administration.
Conclusions:
- TRAIL-functionalized nanoparticles represent a promising strategy for precision oncology, combining molecular therapeutics with nanotechnology.
- This approach holds significant translational potential for personalized cancer treatment by enhancing TRAIL efficacy and reducing toxicity.
- Further research and development are needed to advance TRAIL nanomedicines toward clinical application.
More Related Videos
10:51Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Non-invasive Hyperthermia Cancer Therapy
Published on: August 28, 2013
08:07Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test
Published on: November 23, 2019
Related Concept Videos
Mechanical Protein Functions
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mechanical Protein Function
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...